AJOVY is indicated for the preventive treatment of migraine in adults.

AJOVY is a sterile, clear to opalescent, colorless to slightly yellow solution, available as follows:

• Injection: 225 mg/1.5 mL single-dose prefilled autoinjector
• Injection: 225 mg/1.5 mL single-dose prefilled syringe

AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.1)].

The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:

• Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
• Hypertension [see Warnings and Precautions (5.2)]
• Raynaud’s Phenomenon [see Warnings and Precautions (5.3)]

Fremanezumab-vfrm is a fully humanized IgG2Δa/kappa monoclonal antibody specific for calcitonin gene-related peptide (CGRP) ligand. Fremanezumab-vfrm is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells. The antibody consists of 1324 amino acids and has a molecular weight of approximately 148 kDa.

AJOVY (fremanezumab-vfrm) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow solution for subcutaneous injection, supplied in a single-dose 225 mg/1.5 mL prefilled autoinjector and a single-dose 225 mg/1.5 mL prefilled syringe.

Each prefilled autoinjector or prefilled syringe delivers 1.5 mL of solution containing 225 mg fremanezumab-vfrm, disodium ethylenediaminetetraacetic acid dihydrate (EDTA) (0.204 mg), L-histidine (0.815 mg), L-histidine hydrochloride monohydrate (3.93 mg), polysorbate-80 (0.3 mg), sucrose (99 mg), and Water for Injection, and has a pH of 5.5.

The efficacy of AJOVY was evaluated as a preventive treatment of episodic or chronic migraine in two multicenter, randomized, 3-month, double-blind, placebo-controlled studies (Study 1 and Study 2, respectively).

Episodic Migraine

Study 1 (NCT 02629861) included adults with a history of episodic migraine (patients with <15 headache days per month). All patients were randomized (1:1:1) to receive subcutaneous injections of either AJOVY 675 mg every three months (quarterly), AJOVY 225 mg monthly, or placebo monthly, over a 3-month treatment period. Patients were allowed to use acute headache treatments during the study. A subset of patients (21%) was allowed to use one additional concomitant preventive medication.

The study excluded patients with a history of significant cardiovascular disease, vascular ischemia, or thrombotic events, such as cerebrovascular accident, transient ischemic attacks, deep vein thrombosis, or pulmonary embolism.

The primary efficacy endpoint was the mean change from baseline in the monthly average number of migraine days during the 3-month treatment period. Secondary endpoints included the proportion of patients reaching at least a 50% reduction in monthly average number of migraine days during the 3-month treatment period, the mean change from baseline in the monthly average number of days of use of any acute headache medication during the 3-month treatment period, and the mean change from baseline in the number of migraine days during the first month of the treatment period.

In Study 1, a total of 875 patients (742 females, 133 males), ranging in age from 18 to 70 years, were randomized. A total of 791 patients completed the 3-month double-blind phase. The mean migraine frequency at baseline was approximately 9 migraine days per month, and was similar across treatment groups.

Both monthly and quarterly dosing regimens of AJOVY demonstrated statistically significant improvements for efficacy endpoints compared to placebo over the 3-month period, as summarized in Table 2.

Figure 1 displays the mean change from baseline in the average monthly number of migraine days in Study 1.

Figure 1:         Change from Baseline in Monthly Migraine Days in Study 1a

Figure 2 shows the distribution of change from baseline in mean monthly migraine days in bins of 2 days by treatment group in Study 1. A treatment benefit over placebo for both doses of AJOVY is seen across a range of changes from baseline in monthly migraine days.

Figure 2:          Distribution of Change from Baseline in Mean Monthly Migraine Days by Treatment Group in Study 1

Chronic Migraine

Study 2 (NCT 02621931) included adults with a history of chronic migraine (patients with ≥15 headache days per month). All patients were randomized (1:1:1) to receive subcutaneous injections of either AJOVY 675 mg starting dose followed by 225 mg monthly, 675 mg every 3 months (quarterly), or placebo monthly, over a 3-month treatment period. Patients were allowed to use acute headache treatments during the study. A subset of patients (21%) was allowed to use one additional concomitant, preventive medication.

The study excluded patients with a history of significant cardiovascular disease, vascular ischemia, or thrombotic events, such as cerebrovascular accident, transient ischemic attacks, deep vein thrombosis, or pulmonary embolism.

The primary efficacy endpoint was the mean change from baseline in the monthly average number of headache days of at least moderate severity during the 3-month treatment period. The secondary endpoints were the mean change from baseline in the monthly average number of migraine days during the 3-month treatment period, the proportion of patients reaching at least 50% reduction in the monthly average number of headache days of at least moderate severity during the 3-month treatment period, the mean change from baseline in the monthly average number of days of use of any acute headache medication during the 3-month treatment period, and the mean change from baseline in the number of headache days of at least moderate severity during the first month of treatment.

In Study 2, a total of 1130 patients (991 females, 139 males), ranging in age from 18 to 70 years, were randomized. A total of 1034 patients completed the 3-month double-blind phase.

Both monthly and quarterly dosing regimens of AJOVY treatment demonstrated statistically significant improvement for key efficacy outcomes compared to placebo, as summarized in Table 3.

aIn Study 2, patients received a 675 mg starting dose.
bUsed for chronic migraine diagnosis.
cUsed for primary endpoint analysis.

Figure 3 displays the mean change from baseline in the average monthly number of headache days of at least moderate severity in Study 2.

Figure 3:         Change from Baseline in Monthly Headache Days of At Least Moderate Severity in Study 2a

Figure 4 shows the distribution of change from baseline in monthly headache days of at least moderate severity at month 3 in bins of 3 days by treatment group. A treatment benefit over placebo for both dosing regimens of AJOVY is seen across a range of changes from baseline in headache days.

Figure 4:         Distribution of Mean Change from Baseline in Monthly Headache Days of At Least Moderate Severity by Treatment Group in Study 2

*In Study 2, patients received a 675 mg starting dose.

Advise the patient and/or caregiver to read the FDA-approved patient labeling (Patient Information and Instructions for Use).

Information on Preparation and Administration

Provide guidance to patients and caregivers on proper subcutaneous administration technique, including aseptic technique, and how to use the single-dose prefilled syringe [see Dosage and Administration (2.2)]. Instruct patients and/or caregivers to read and follow the Instructions for Use each time they use AJOVY.

Instruct patients prescribed the regimen of 675 mg every 3 months to administer the dosage as three consecutive subcutaneous injections of 225 mg each [see Dosage and Administration (2.1)].

Hypersensitivity Reactions

Inform patients about the signs and symptoms of hypersensitivity reactions and that these reactions can occur up to 1 month after administration. Advise patients to contact their healthcare provider immediately if signs or symptoms of hypersensitivity reactions occur [see Warnings and Precautions (5.1)].

Hypertension

Inform patients that hypertension can develop or pre-existing hypertension can worsen with AJOVY, and that they should contact their healthcare provider if they experience elevation in their blood pressure [see Warnings and Precautions (5.2)].

Raynaud's Phenomenon

Inform patients that Raynaud’s phenomenon can develop or worsen with AJOVY. Advise patients to discontinue AJOVY and contact their healthcare provider if they experience signs or symptoms of Raynaud’s phenomenon [see Warnings and Precautions (5.3)].

Pregnancy

Advise women that there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to AJOVY during pregnancy [see Use in Specific Populations (8.1)].

Manufactured by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
US License No. 2016

AJOVY® (fremanezumab-vfrm), its use, or its process of manufacture, may be protected by one or more United States patents, including US 8,007,794, US 8,586,045 and US 9,896,502.

©2025 Teva Pharmaceuticals USA, Inc.

AJO-011

This Patient Information has been approved by the U.S. Food and Drug Administration.                                  Revised: 3/2025

AJOVY® (a-JO-vee)
(fremanezumab-vfrm) injection
prefilled autoinjector, for subcutaneous use

For subcutaneous injection only.

Read and follow the Instructions for Use for your AJOVY prefilled autoinjector before you start using it and each time you get a refill.

Important:

• AJOVY prefilled autoinjector is for single-time (one-time) use only. Put AJOVY in a FDA-cleared sharps disposal or puncture-resistant container right away after use. Do not throw away (dispose of) your used sharps disposal container in your household trash.
• Before injecting, let AJOVY sit at room temperature for 30 minutes.
• Keep AJOVY prefilled autoinjector out of the reach of small children.
• After you remove the protective cap from AJOVY, to prevent infection, do not touch the needle.
• Do not inject AJOVY in your veins (intravenously).
• Do not re-use your AJOVY prefilled autoinjector as this could cause injury or infection.
• Do not share your AJOVY prefilled autoinjector with another person. You may give another person an infection or get an infection from them.

You may give AJOVY yourself. If you feel uncomfortable, you should not get your first dose of AJOVY until you or your caregiver receive training from a healthcare provider on the right way to use AJOVY.

Storage Conditions:

• Store AJOVY in the refrigerator between 36°F to 46°F (2°C to 8°C).
• Keep AJOVY in the carton it comes in to protect from light.
• If needed, AJOVY may be stored at room temperature up to 86°F (30°C) in the carton it comes in for up to 7 days. Do not use AJOVY if it has been out of the refrigerator for 7 days or longer. Throw away (dispose of) AJOVY in a sharps disposal or puncture-resistant container if it has been out of the refrigerator for 7 days or longer. Once stored at room temperature, do not place back in the refrigerator.
• Do not freeze. If AJOVY freezes, throw it away in a sharps disposal container.
• Keep AJOVY out of extreme heat and direct sunlight.

Do not shake AJOVY.

AJOVY prefilled autoinjector (Before use). See Figure A.

Figure A

AJOVY prefilled autoinjector (After use). See Figure B.

Figure B

• The blue plunger moves down the viewing window during the injection. The blue plunger fills the window when the injection is complete. Note: When the blue plunger has filled the viewing window you will still be able to see the gray stopper, as shown in Figure B.
• When injecting AJOVY, hold the prefilled autoinjector so that your hand does not cover the viewing window.

     Read this before you inject.

Step 1. Check the dose your healthcare provider has prescribed.

AJOVY comes as a single-dose (one time) prefilled autoinjector. Your healthcare provider will prescribe the dose that is best for you.

• If your healthcare provider has prescribed 225 mg of AJOVY each month for you, give 1 injection each month, using a 225 mg prefilled AJOVY autoinjector.
• If your healthcare provider has prescribed 675 mg of AJOVY every 3 months for you, give 3 separate injections, one after another, using a different 225 mg prefilled AJOVY autoinjector for each injection. Give these injections 1 time every 3 months.

Before you inject, always check the label of your single-dose prefilled autoinjector to make sure you have the correct medicine and the correct dose of AJOVY. If you are not sure of your dose, ask your healthcare provider.

How do I inject AJOVY?

Step 2. Remove the prefilled autoinjector from the carton.

• You may need to use more than 1 prefilled autoinjector depending on your prescribed dose.
• Remove the autoinjector from the carton (see Figure C).
• Do not shake the prefilled autoinjector at any time, as this could affect the way the medicine works.
  

 Important: If there are any unused autoinjectors left in the carton, put the carton and unused autoinjectors back in the refrigerator.

Figure C

Step 3. Gather the supplies you will need to inject AJOVY.

• Gather the following supplies (see Figure D) and the number of AJOVY 225 mg prefilled autoinjectors you will need to give your prescribed dose:

- If your dose is 225 mg, you will need 1 AJOVY 225 mg prefilled autoinjector.

- If your dose is 675 mg, you will need 3 AJOVY 225 mg prefilled autoinjectors.

- Alcohol swabs (not supplied).

- Gauze pads or cotton balls (not supplied).

- Sharps disposal or puncture-resistant container (not supplied).

Figure D

Step 4. Let AJOVY reach room temperature.

• Place the supplies you have gathered on a clean, flat surface.
• Wait for 30 minutes to allow the medicine to reach room temperature.
• Do not leave the prefilled autoinjector in direct sunlight.
• Do not warm up the AJOVY prefilled autoinjector using a heat source such as hot water or a microwave.

Step 5. Wash your hands.

• Wash your hands with soap and water and dry well with a clean towel. Be careful not to touch your face or hair after washing your hands.

Step 6. Look closely at your AJOVY prefilled autoinjector.

Note: You may see air bubbles in the prefilled autoinjector. This is normal. Do not remove the air bubbles from the prefilled autoinjector before giving your injection.

Injecting AJOVY with these air bubbles will not harm you.

Figure E

Step 7: Choose your injection area.

• Choose an injection area from the following areas (see Figure F):
  • your stomach area (abdomen), avoid about 2 inches around the belly button.
  • the front of your thighs, an area that is at least 2 inches above the knee and 2 inches below the groin.
  • the back of your upper arms, in the fleshy area of the upper back portion.

Figure F

 Note: There are some injection areas on your body that are hard to reach (like the back of your arm). You may need help from someone who has been instructed on how to give your injection if you cannot reach certain injection areas.

Step 8. Clean your injection area.

• Clean the chosen injection area using a new alcohol swab. Let your skin dry.

• Do not inject AJOVY into an area that is tender, red, bruised, callused, tattooed, hard, or that has scars or stretch marks.

• Do not inject AJOVY in the same injection site that you inject other medicine.
• If you want to use the same injection area for the 3 separate injections needed for the 675 mg dose, make sure the second and third injections are not at the same spot you used for the other injections.

Step 9. Remove protective cap and do not replace.

• Pick up the prefilled autoinjector in 1 hand.
• Hold the prefilled autoinjector as shown in Figure G and pull the protective cap straight off with your other hand. Do not twist.
• Throw away the protective cap right away.
• Do not put the protective cap back on the prefilled autoinjector, to avoid injury and infection.

Figure G

Step 10. Give your injection.

• 10.1 Place the prefilled autoinjector at a 90 degree angle against your skin at the injection site you have cleaned (see Figure H).

Figure H

10.2 Press down on the prefilled autoinjector and keep holding it down against the skin for about 30 seconds. Do not remove pressure until the 3 steps below are complete.
1. You hear the first “click” (this means the injection has started and the blue plunger starts to move).	2. You hear a second “click” (about 15 seconds after the first click. The plunger will be moving to the bottom of the viewing window as the medicine is being injected.)	3. You wait another 10 seconds. (to make sure all the medicine is injected).

10.3 Check that the blue plunger has filled the viewing window and remove the autoinjector from the skin by lifting the prefilled autoinjector straight up (see Figure I).

Note: When the blue plunger has filled the viewing window you will be able to see the gray stopper.

As the prefilled autoinjector is lifted from the skin, the needle shield returns to the original (before use) position and locks into place, covering the needle.

Do not try to put the protective cap back on the used prefilled autoinjector as it is no longer needed.

Do not try to re-use the prefilled autoinjector.

Figure I

 Step 11. Apply pressure to the injection site.

• Use a clean, dry cotton ball, or gauze pad to gently press on the injection site for a few seconds.
• Do not rub the injection site.

• Do not re-use the prefilled autoinjector.

Step 12. Dispose of your prefilled autoinjector right away.

• Put your used prefilled autoinjectors in a FDA-cleared sharps disposal container right away after use.
• Do not throw away (dispose of) prefilled autoinjectors in your household trash. Do not recycle your used sharps disposal container.
• If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
  • made of a heavy-duty plastic,
  • can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
  • upright and stable during use,
  • leak-resistant, and
  • properly labeled to warn of hazardous waste inside the container.
• When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used autoinjectors. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal
• Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

Injection Complete

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
US License No. 2016

©2020 Teva Pharmaceuticals USA, Inc.

AJOIFU-AI-004
Approved: 10/2020

AJOVY® (a-JO-vee)
(fremanezumab-vfrm) injection
prefilled syringe, for subcutaneous use

For subcutaneous injection only.

Read and follow the Instructions for Use for your AJOVY prefilled syringe before you start using it and each time you get a refill.

Important:

• AJOVY prefilled syringe is for single-time (one-time) use only. Put AJOVY in a FDA-cleared sharps disposal or puncture-resistant container right away after use. Do not throw away (dispose of) your used sharps disposal container in your household trash.
• Before injecting, let AJOVY sit at room temperature for 30 minutes.
• Keep AJOVY prefilled syringe out of the reach of small children.
• After you remove the needle cap from AJOVY, to prevent infection, do not touch the needle.
• Do not pull back on the plunger at any time, as this can break the prefilled syringe.
• Do not inject AJOVY in your veins (intravenously).
• Do not re-use your AJOVY prefilled syringe, as this could cause injury or infection.
• Do not share your AJOVY prefilled syringe with another person. You may give another person an infection or get an infection from them.

You may give AJOVY yourself. If you feel uncomfortable, you should not get your first dose of AJOVY until you or your caregiver receive training from a healthcare provider on the right way to use AJOVY.

Storage Conditions:

• Store AJOVY in the refrigerator between 36°F to 46°F (2°C to 8°C).
• Keep AJOVY in the carton it comes in to protect from light.
• If needed, AJOVY may be stored at room temperature up to 86°F (30°C) in the carton it comes in for up to 7 days. Do not use AJOVY if it has been out of the refrigerator for 7 days or longer. Throw away (dispose of) AJOVY in a sharps disposal or puncture-resistant container if it has been out of the refrigerator for 7 days or longer. Once stored at room temperature, do not place back in the refrigerator.
• Do not freeze. If AJOVY freezes, throw it away in a sharps disposal container.
• Keep AJOVY out of extreme heat and direct sunlight.
• Do not shake AJOVY.

AJOVY prefilled syringe (Before use). See Figure A.

Figure A

AJOVY prefilled syringe (After use). See Figure B.

Figure B

Read this before you inject.

Step 1. Check the dose your healthcare provider has prescribed.

AJOVY comes as a single-dose (one time) prefilled syringe. Your healthcare provider will prescribe the dose that is best for you.

• If your healthcare provider has prescribed 225 mg of AJOVY each month for you, give 1 injection each month using a 225 mg prefilled AJOVY syringe.

• If your healthcare provider has prescribed 675 mg of AJOVY every 3 months for you, give 3 separate injections, one after another, using a different 225 mg prefilled AJOVY syringe for each injection. Give these injections 1 time every 3 months.

Before you inject, always check the label of your single-dose prefilled syringe to make sure you have the correct medicine and the correct dose of AJOVY. If you are not sure of your dose, ask your healthcare provider.

How do I inject AJOVY?

Step 2. Remove the prefilled syringe from the carton.

• You may need to use more than 1 prefilled syringe depending on your prescribed dose.
• Hold the prefilled syringe (as shown in Figure C).
• Remove the syringe from the carton.
• Do not shake the prefilled syringe at any time, as this could affect the way the medicine works.

Figure C

Step 3. Gather the supplies you will need to inject AJOVY.

• Gather the following supplies (see Figure D) and the number of AJOVY 225 mg prefilled syringes you will need to give your prescribed dose:

- If your dose is 225 mg, you will need 1 AJOVY 225 mg prefilled syringe.

- If your dose is 675 mg, you will need 3 AJOVY 225 mg prefilled syringes.

- alcohol swabs (not supplied).

- gauze pads or cotton balls (not supplied).

- sharps disposal or puncture-resistant container (not supplied).

Figure D

 Step 4. Let AJOVY reach room temperature.

• Place the supplies you have gathered on a clean, flat surface.
• Wait for 30 minutes to allow the medicine to reach room temperature.
• Do not leave the prefilled syringe in direct sunlight.
• Do not warm up the AJOVY prefilled syringe using a heat source such as hot water or a microwave.

Step 5. Wash your hands.

• Wash your hands with soap and water and dry well with a clean towel. Be careful not to touch your face or hair after washing your hands.

Step 6. Look closely at your AJOVY prefilled syringe.

Note: You may see air bubbles in the prefilled syringe. This is normal. Do not remove the air bubbles from the prefilled syringe before giving your injection. Injecting AJOVY with these air bubbles will not harm you.

Figure E

Step 7. Choose your injection area.

• Choose an injection area from the following areas (see Figure F):

• your stomach area (abdomen), avoid about 2 inches around the belly button.
• the front of your thighs, an area that is at least 2 inches above the knee and 2 inches below the groin.
• the back of your upper arms, in the fleshy area of the upper back portion.

Figure F

Note: There are some injection areas on your body that are hard to reach (like the back of your arm). You may need help from someone who has been instructed on how to give your injection if you cannot reach certain injection areas.

Step 8. Clean your injection area.

• Clean the chosen injection area using a new alcohol swab. Let your skin dry.
  
• Do not inject AJOVY into an area that is tender, red, bruised, callused, tattooed, hard, or that has scars or stretch marks.
• Do not inject AJOVY in the same injection site that you inject other medicine.
• If you want to use the same injection area for the 3 separate injections needed for the 675 mg dose, make sure the second and third injections are not at the same spot you used for the other injections.

Step 9. Remove needle cap and do not replace.

• Pick up the body of the prefilled syringe with 1 hand.
• Pull the needle cap straight off with your other hand (see Figure G). Do not twist.
• Throw away the needle cap right away.
• Do not put the needle cap back on the prefilled syringe, to avoid injury and infection.

Figure G

Step 10. Give your injection following the 4 steps below.

1. Use your free hand to gently pinch up at least 1 inch of the skin that you have cleaned.	2. Insert the needle into the pinched skin at a 45 to 90 degree angle.	3. When the needle is all the way into your skin, use your thumb to push the plunger.	4. Push the plunger slowly all the way down as far as it will go to inject all of the medicine.

Step 11. Remove the needle from your skin.

• After you have injected all of the medicine, pull the needle straight out (see Figure H).
• Do not recap the needle at any time to avoid injury and infection.

Figure H

Step 12. Apply pressure to the injection site.

• Use a clean, dry cotton ball or gauze to gently press on the injection site for a few seconds.
• Do not rub the injection site.
• Do not re-use the prefilled syringe.

Step 13. Dispose of your prefilled syringe right away.

• Put your used prefilled syringes, needles, and sharps in a FDA-cleared sharps disposal container right away after use.
• Do not throw away (dispose of) loose needles, syringes, or prefilled syringes in your household trash. Do not recycle your used sharps disposal container.
• If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:

• made of a heavy-duty plastic,
• can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,
• upright and stable during use,
• leak-resistant, and
• properly labeled to warn of hazardous waste inside the container.

• When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal
• Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.

Injection Complete

This Instructions for Use has been approved by the U.S. Food and Drug Administration.

Manufactured by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
US License No. 2016

©2020 Teva Pharmaceuticals USA, Inc.

AJOIFU-PFS-004

Revised: 10/2020

NDC 51759-204-10
Rx only
AJOVY® (fremanezumab-vfrm) injection 225 mg/1.5 mL
FOR SUBCUTANEOUS USE ONLY
One single-dose prefilled syringe
Store in refrigerator at 36°F to 46°F (2° to 8°C) in the original carton to protect from light. DO NOT FREEZE. DO NOT SHAKE. If needed, AJOVY® may be kept at room temperature up to 86°F (30°C) for 7 days. Once stored at room temperature, do not place back in the refrigerator. Discard after 7 days.

OPEN HERE
teva

NDC 51759-202-10
Rx only
AJOVY (fremanezumab-vfrm) injection 225 mg/1.5 mL
FOR SUBCUTANEOUS USE ONLY
One single-dose prefilled autoinjector
Store in refrigerator at 36°F to 46°F (2° to 8°C) in the original carton to protect from light. DO NOT FREEZE. DO NOT SHAKE. If needed, AJOVY® may be kept at room temperature up to 86°F (30°C) for 7 days. Once stored at room temperature, do not place back in the refrigerator. Discard after 7 days.

OPEN HERE
teva

NDC 51759-202-22
Rx only
AJOVY (fremanezumab-vfrm) injection 225 mg/1.5 mL
FOR SUBCUTANEOUS USE ONLY
3 x 225 mg/1.5 mL single-dose prefilled autoinjectors
Store in refrigerator at 36°F to 46°F (2° to 8°C) in the original carton to protect from light. DO NOT FREEZE. DO NOT SHAKE. If needed, AJOVY® may be kept at room temperature up to 86°F (30°C) for 7 days. Once stored at room temperature, do not place back in the refrigerator. Discard after 7 days.

OPEN HERE
teva